Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-003191-23
    Sponsor's Protocol Code Number:ANZUP1303
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-09-27
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-003191-23
    A.3Full title of the trial
    Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer.
    Studio di fase 3 randomizzato di enzalutamide nella terapia di deprivazione androgenica associata a radioterapia per il carcinoma prostatico clinicamente localizzato ad alto rischio.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Research study that is testing a new treatment combination for localised prostate cancer that is going to be treated with radiotherapy. This study is
    looking at combining a new drug, enzalutamide, with the current best available treatments in order to improve outcomes for men in this situation. This is a randomised controlled trial which means that half the participants on the trial will get enzalutamide and the other half will get current standard of care.
    Studio di fase 3 randomizzato di enzalutamide nella terapia di deprivazione androgenica associata a radioterapia per il carcinoma prostatico clinicamente localizzato ad alto rischio.
    A.3.2Name or abbreviated title of the trial where available
    ENZARAD Trial
    ENZARAD studio
    A.4.1Sponsor's protocol code numberANZUP1303
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberISRCTN12614000
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02446444
    A.5.4Other Identifiers
    Name:/Number:/
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIRISH CLINICAL ONCOLOGY RESEARCH GROUP CLG, TRADING AS CANCER TRIALS IRELAND
    B.1.3.4CountryIreland
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNHMRC Clinical Trials Centre (CTC)
    B.4.2CountryAustralia
    B.4.1Name of organisation providing supportANZUP
    B.4.2CountryAustralia
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIrish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    B.5.2Functional name of contact pointOlwyn Deignan
    B.5.3 Address:
    B.5.3.1Street Address60 Fitzwilliam Square
    B.5.3.2Town/ cityDublin
    B.5.3.3Post code2
    B.5.3.4CountryIreland
    B.5.4Telephone number+353 1 6677211
    B.5.5Fax number+353 1 6697869
    B.5.6E-mailOlwyn.Deignan@cancertrials.ie
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Xtandi (Enzalutamide)
    D.2.1.1.2Name of the Marketing Authorisation holderAstellas Pharma US, Inc.,US
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNENZALUTAMIDE
    D.3.9.1CAS number 915087-33-1
    D.3.9.2Current sponsor code/
    D.3.9.3Other descriptive name/
    D.3.9.4EV Substance CodeSUB77412
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Bicalutamide
    D.2.1.1.2Name of the Marketing Authorisation holder/
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBICALUTAMIDE
    D.3.9.1CAS number 90357-06-5
    D.3.9.2Current sponsor code/
    D.3.9.3Other descriptive name/
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Flutamide
    D.2.1.1.2Name of the Marketing Authorisation holder/
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUTAMIDE
    D.3.9.1CAS number 13311-84-7
    D.3.9.2Current sponsor code/
    D.3.9.3Other descriptive name/
    D.3.9.4EV Substance CodeAS3
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Nilutamide
    D.2.1.1.2Name of the Marketing Authorisation holder/
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNILUTAMIDE
    D.3.9.1CAS number 63612-50-0
    D.3.9.2Current sponsor code/
    D.3.9.3Other descriptive name/
    D.3.9.4EV Substance CodeAS4
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Localised prostate cancer at high risk of recurrence
    Il cancro alla prostata localizzato ad alto rischio di recidiva


    E.1.1.1Medical condition in easily understood language
    Localised prostate cancer at high risk of recurrence
    Il cancro alla prostata localizzato ad alto rischio di recidiva
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10060862
    E.1.2Term Prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the effectiveness of enzalutamide as part of adjuvant ADT
    with a LHRHA in men having RT for localised prostate cancer at high risk
    of recurrence.
    To determine effects on:
    1) Overall survival (death from any cause)
    Stabilire gli effetti su:
    1) Sopravvivenza globale (decesso per qualsiasi causa)
    E.2.2Secondary objectives of the trial
    To determine effects on:
    2) Cause-specific survival (prostate cancer, and other causes)
    3) PSA progression free survival (Phoenix criteria)
    4) Clinical progression free survival
    5) Time to subsequent hormonal therapy (restarting ADT)
    6)Time to castration-Resistant disease (PCWG2 criteria)
    7) Metastasis - Free survival
    8) Adverse events (CTCAE v4.03)
    9) Health related quality of life (EORTC QLQC-30,PR-25 & EQ-5D-5L)
    10) Health outcomes relative to costs (incremental cost effectiveness
    ratio)
    Stabilire gli effetti su:
    2) Sopravvivenza specifica alla causa (tumore prostatico, altre cause)
    3) Sopravvivenza libera da progressione del PSA (criteri di Phoenix)
    4) Sopravvivenza libera da progressione clinica
    5) Tempo alla successiva terapia ormonale (riavvio dell’ADT)
    6) Tempo alla malattia resistente alla castrazione (criteri PCWG2)
    7) Sopravvivenza libera da metastasi (MFS)
    8) Eventi avversi (CTCAE v4.03)
    9) Qualità della vita associata alle condizioni di salute (EORTC QLQC-30, PR-25 ed EQ-5D-5L)
    10) Esiti della salute in relazione ai costi (rapporto costo-efficacia incrementale)
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: To identify biomarkers that are prognostic and/or predictive of response
    to treatment, safety and resistance to study treatment (associations of
    biomarkers with clinical outcomes) , Included in Protocol Version 1, 11-Nov-2013

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: To identify biomarkers that are prognostic and/or predictive of response
    to treatment, safety and resistance to study treatment (associations of
    biomarkers with clinical outcomes) , Included in Protocol Version 1, 11- Nov-2013
    E.3Principal inclusion criteria
    1. Pathological diagnosis of adenocarcinoma of the prostate, judged to be at high risk for recurrence based on any of the following (in accordance with the ISUP Consensus 2005 (13) see Appendix 3):
    ¿ Gleason score 8-10
    OR
    ¿ Gleason score of 4+3 AND clinical T2b-4 AND PSA >20ng/mL OR
    ¿ N1 disease (involvement of lymph nodes at or below the bifurcation
    of the common iliac arteries) defined radiologically as greater than
    10mm on short axis using standard CT or MRI, or biopsy proven
    2. Age =18 yrs
    3. Adequate bone marrow function Hb =100g/L and WCC = 4.0 x 109/L
    and platelets =100 x 109/L
    4. Adequate liver function: ALT < 2 x ULN and bilirubin < 1.5 x ULN, (or
    if bilirubin is between 1.5 - 2 x ULN, they must have a normal conjugated
    bilirubin).
    5. Adequate renal function: calculated creatinine clearance > 30
    ml/min (Cockroft-Gault)
    6. ECOG performance status of 0-1
    7. Study treatment both planned and able to start within 7 days of
    randomisation.
    8. Willing and able to comply with all study requirements, including
    treatment, and attending required assessments
    9. Has completed the baseline HRQOL questionnaires UNLESS is unable
    to complete because of literacy or limited vision
    10. Signed, written, informed consent
    1. Diagnosi patologica di adenocarcinoma della prostata, giudicato ad alto rischio di recidiva sulla base di uno qualsiasi dei seguenti elementi (in conformità con il Consenso ISUP 2005
    (13) ee Appendice 3):
    ¿ Punteggio di Gleason 8-10
    OPPURE
    ¿ Punteggio di Gleason 4+3 E T2b-4 clinico E PSA > 20ng/ml
    OPPURE
    ¿ Malattia N1 (interessamento dei linfonodi a livello o sotto la biforcazione delle arterie iliache comuni) radiologicamente definita come superiore a 10 mm sull’asse corto usando una TC o RMI standard o comprovata da biopsia
    2. Età = 18 anni
    3. Funzionalità del midollo osseo adeguata: Hb = 100g/l e conta leucocitaria = 4,0 x 109/l e piastrine = 100 x 109/l
    4. Funzionalità epatica adeguata: ALT < 2 x ULN e bilirubina < 1,5 x ULN (oppure se la bilirubina è compresa tra 1,5 e 2 x ULN, è necessario presentare un valore normale per la bilirubina coniugata).
    5. Funzionalità renale adeguata: clearance della creatinina calcolata > 30 ml/min (Cockroft-Gault)
    6. Stato di performance ECOG di 0-1
    7. Trattamento dello studio programmato e avviabile entro 7 giorni dalla randomizzazione.
    8. Disponibilità e capacità di conformarsi a tutti i requisiti dello studio, incluso il trattamento e la presentazione alle visite richieste
    9. Ha completato i questionari HRQOL al basale A MENO CHE non sia in grado di completarli in quanto non è in grado di leggere o ha una vista limitata
    10. Consenso informato scritto firmato
    E.4Principal exclusion criteria
    1. Carcinoma prostatico con significativo componente di cellule neuroendocrine piccole o cellule del mandrino o sarcomatoide
    2. Coinvolgimento dei linfonodi al di sopra della biforcazione iliaca comune e/o esterni alla pelvi (linfonodi distanti). Il coinvolgimento linfonodale è definito con conferma istopatologica o mediante una misurazione dell’asse corto > 10 mm negli esami di diagnostica per immagini standard (TC o RMI, ma non nella PET).
    3. Qualsiasi controindicazione alla radioterapia a fasci esterni
    4. Anamnesi di
    a. crisi convulsiva o qualsiasi condizione che possa predisporre a crisi convulsive (ad esempio precedente ictus corticale o significativo trauma cerebrale).
    b. perdita di coscienza o attacco ischemico transitorio nei 12 mesi precedenti alla randomizzazione
    c. significativa malattia cardiovascolare negli ultimi 3 mesi:
    incluso infarto del miocardio, angina instabile, insufficienza cardiaca congestizia (grado NYHA II o superiore, vedere Appendice 4), aritmie in corso di grado > 2 (NCI CTCAE, versione 4.03), eventi tromboembolici (ad esempio trombosi venosa profonda, embolia polmonare). È consentita la fibrillazione atriale cronica stabile con terapia anticoagulante stabile.
    5. Evidenza di malattia metastatica: è richiesto almeno un esame di diagnostica per immagini con TC/RMI e scintigrafia ossea globale scheletrica (WBBS). In caso di dubbi alla scintigrafia ossea, sono necessari esami radiografici diretti di follow-up che dimostrino l’ASSENZA del tumore, se non presenti mediante TC/RMI
    6. PSA > 100 ng/ml
    7. Anamnesi di un’altra neoplasia maligna nei 5 anni precedenti alla randomizzazione, fatta eccezione per il carcinoma della pelle non melanomatoso; oppure, carcinoma uroteliale della vescica non muscolo invasivo adeguatamente trattato (ovvero tumori di basso grado T1, Tis e Ta).
    8. Malattia concomitante, tra cui grave infezione che può compromettere la capacità del paziente di sottoporsi alle procedure indicate in questo protocollo con ragionevole sicurezza
    a. L’infezione da HIV non è un criterio di esclusione se è controllata con farmaci antiretrovirali che non vengono influenzati dall’uso concomitante di enzalutamide.
    9. Presenza di qualunque condizione psicologica, familiare, sociologica o geografica che costituisca un potenziale ostacolo alla conformità con il protocollo dello studio e al programma di follow-up, tra cui dipendenza da alcol o abuso di sostanze stupefacenti;
    10. Pazienti con vita sessuale attiva non disposti/in grado di usare metodi contraccettivi a barriera clinicamente accettabili.
    11. Uso di terapia ormonale o terapia di deprivazione androgenica, tra cui enzalutamide, fatta eccezione per i seguenti casi:
    a. Uso di LHRHA (con o senza antiandrogeni) per meno di 30 giorni prima della randomizzazione in questa sperimentazione.
    12. Orchiectomia bilaterale o prostatectomia radicale
    13. Previa brachiterapia o altra radioterapia che potrebbe causare una sovrapposizione radioterapica
    14. Partecipazione ad altre sperimentazioni cliniche di agenti sperimentali per il trattamento del tumore prostatico o altre malattie.
    15. Intervento chirurgico maggiore nei 21 giorni precedenti la randomizzazion
    1. Carcinoma prostatico con significativo componente di cellule neuroendocrine piccole o cellule del mandrino o sarcomatoide
    2. Coinvolgimento dei linfonodi al di sopra della biforcazione iliaca comune e/o esterni alla pelvi (linfonodi distanti). Il coinvolgimento linfonodale è definito con conferma istopatologica o mediante una misurazione dell’asse corto > 10 mm negli esami di diagnostica per immagini standard (TC o RMI, ma non nella PET).
    3. Qualsiasi controindicazione alla radioterapia a fasci esterni
    4. Anamnesi di
    a. crisi convulsiva o qualsiasi condizione che possa predisporre a crisi convulsive (ad esempio precedente ictus corticale o significativo trauma cerebrale).
    b. perdita di coscienza o attacco ischemico transitorio nei 12 mesi precedenti alla randomizzazione
    c. significativa malattia cardiovascolare negli ultimi 3 mesi:
    incluso infarto del miocardio, angina instabile, insufficienza cardiaca congestizia (grado NYHA II o superiore, vedere Appendice 4), aritmie in corso di grado > 2 (NCI CTCAE, versione 4.03), eventi tromboembolici (ad esempio trombosi venosa profonda, embolia polmonare). È consentita la fibrillazione atriale cronica stabile con terapia anticoagulante stabile.
    5. Evidenza di malattia metastatica: è richiesto almeno un esame di diagnostica per immagini con TC/RMI e scintigrafia ossea globale scheletrica (WBBS). In caso di dubbi alla scintigrafia ossea, sono necessari esami radiografici diretti di follow-up che dimostrino l’ASSENZA del tumore, se non presenti mediante TC/RMI
    6. PSA > 100 ng/ml
    7. Anamnesi di un’altra neoplasia maligna nei 5 anni precedenti alla randomizzazione, fatta eccezione per il carcinoma della pelle non melanomatoso; oppure, carcinoma uroteliale della vescica non muscolo invasivo adeguatamente trattato (ovvero tumori di basso grado T1, Tis e Ta).
    8. Malattia concomitante, tra cui grave infezione che può compromettere la capacità del paziente di sottoporsi alle procedure indicate in questo protocollo con ragionevole sicurezza
    a. L’infezione da HIV non è un criterio di esclusione se è controllata con farmaci antiretrovirali che non vengono influenzati dall’uso concomitante di enzalutamide.
    9. Presenza di qualunque condizione psicologica, familiare, sociologica o geografica che costituisca un potenziale ostacolo alla conformità con il protocollo dello studio e al programma di follow-up, tra cui dipendenza da alcol o abuso di sostanze stupefacenti;
    10. Pazienti con vita sessuale attiva non disposti/in grado di usare metodi contraccettivi a barriera clinicamente accettabili.
    11. Uso di terapia ormonale o terapia di deprivazione androgenica, tra cui enzalutamide, fatta eccezione per i seguenti casi:
    a. Uso di LHRHA (con o senza antiandrogeni) per meno di 30 giorni prima della randomizzazione in questa sperimentazione.
    12. Orchiectomia bilaterale o prostatectomia radicale
    13. Previa brachiterapia o altra radioterapia che potrebbe causare una sovrapposizione radioterapica
    14. Partecipazione ad altre sperimentazioni cliniche di agenti sperimentali per il trattamento del tumore prostatico o altre malattie.
    15. Intervento chirurgico maggiore nei 21 giorni precedenti la randomizzazion
    E.5 End points
    E.5.1Primary end point(s)
    To determine effects on:
    1) Overall survival (death from any cause)
    Stabilire gli effetti su:
    1) Sopravvivenza globale (decesso per qualsiasi causa)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Cause specific survival is defined as the interval from the date of
    randomisation to the date of last known follow-up alive, or the date of
    death from each of the following causes
    - Prostate Cancer
    - Cardiovascular disease
    - Other causes
    A trial comprising 800 participants that are followed until approximately
    200 deaths are observed (e.g. over a 2 year recruitment with an
    additional follow-up of 5.5 years) provides at least 80% power to detect
    a 33% reduction in the hazard of death with a 2-sided type 1 error of
    0.05 assuming a 5-year survival rate of 76% amongst controls.
    Causa la sopravvivenza specifica è definito come l'intervallo dalla data di
    randomizzazione alla data dell'ultima nota di follow-up in vita, o dalla data di
    morte per ciascuno dei seguenti cause
    - Cancro alla prostata
    - Malattia cardiovascolare
    - Altre cause
    Uno studio che comprende 800 partecipanti che si susseguono fino a circa
    sono stati osservati 200 decessi (per esempio su un reclutamento di 2 anni con un
    ulteriore follow-up di 5,5 anni) prevede almeno l'80% di potenza per rilevare
    una riduzione del 33% del rischio di morte con un 2 lati di tipo 1 errore 0.05 ipotizzando un tasso di sopravvivenza a 5 anni del 76% tra i controlli.
    E.5.2Secondary end point(s)
    To determine effects on:
    2) Cause-specific survival (prostate cancer, and other causes)
    3) PSA progression free survival (Phoenix criteria)
    4) Clinical progression free survival
    5) Time to subsequent hormonal therapy (restarting ADT)
    6) Time to castration-resistant disease (PCWG2 criteria)
    7) Metastasis-free survival
    8) Adverse events (CTCAE v4.03)
    9) Health related quality of life (EORTC QLQC-30,PR-25 & EQ-5D-5L)
    10) Health outcomes relative to costs (incremental cost effectiveness
    ratio)
    Stabilire gli effetti su:
    2) Sopravvivenza specifica alla causa (tumore prostatico, altre cause)
    3) Sopravvivenza libera da progressione del PSA (criteri di Phoenix)
    4) Sopravvivenza libera da progressione clinica
    5) Tempo alla successiva terapia ormonale (riavvio dell’ADT)
    6) Tempo alla malattia resistente alla castrazione (criteri PCWG2)
    7) Sopravvivenza libera da metastasi (MFS)
    8) Eventi avversi (CTCAE v4.03)
    9) Qualità della vita associata alle condizioni di salute (EORTC QLQC-30, PR-25 ed EQ-5D-5L)
    10) Esiti della salute in relazione ai costi (rapporto costo-efficacia incrementale)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Assuming the study is not terminated early, the final analysis is planned
    to be undertaken after the required number of deaths 200 have
    occurred.
    Supponendo che lo studio non viene chiuso anticipatamente, l'analisi finale è prevista
    da intraprendere dopo il numero di decessi si sono verificati 200.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA34
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    New Zealand
    United States
    Austria
    Belgium
    Ireland
    Italy
    Slovenia
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study occurs when all of the following criteria have been
    satisfied:
    1. Thirty days after all patients have stopped protocol treatment
    2. The trial is mature for the analysis of the primary endpoint as
    defined in the protocol
    3. The database has been fully cleaned and frozen for this analysis
    Fine dello studio si verifica quando tutti i seguenti criteri sono stati soddisfatti:
    1. Trenta giorni dopo tutti i pazienti hanno interrotto il trattamento protocollo
    2. Il processo è maturo per l'analisi dell'endpoint primario come definito nel protocollo
    3. Il database è stato completamente ripulito e congelati per questa analisi
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years8
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days17
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 400
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 400
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 400
    F.4.2.2In the whole clinical trial 800
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    If a patient wishes to stop study visits, they will be requested to allow their ongoing health status to be periodically reviewed via continued
    study visits or phone contact or from their general practitioner, or medical records, country specific cancer or mortality registries. All
    adverse events will be followed up for the study for safety reasons for 30 days after the study treatment ends. Study doctor will make arrangements for regular health care to continue.
    Se un paziente desidera smettere di visite di studio, saranno tenuti a consentire il loro stato di salute in corso per un riesame periodico tramite continua
    visite di studio o contatto telefonico o dal loro medico di medicina generale, o cartelle cliniche, il cancro specifico paese o registri di mortalità. Tutti
    eventi avversi saranno seguiti per lo studio per motivi di sicurezza per 30 giorni dopo la fine del trattamento dello studio. Studio medico farà
    disposizioni per l'assistenza sanitaria r
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-04-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-01-26
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:32:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA